Skip to main content

Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities


Wnt signaling is a highly conserved signaling pathway that plays a critical role in controlling embryonic and organ development, as well as cancer progression. Genome-wide sequencing and gene expression profile analyses have demonstrated that Wnt signaling is involved mainly in the processes of breast cancer proliferation and metastasis. The most recent studies have indicated that Wnt signaling is also crucial in breast cancer immune microenvironment regulation, stemness maintenance, therapeutic resistance, phenotype shaping, etc. Wnt/β-Catenin, Wnt–planar cell polarity (PCP), and Wnt–Ca2+ signaling are three well-established Wnt signaling pathways that share overlapping components and play different roles in breast cancer progression. In this review, we summarize the main findings concerning the relationship between Wnt signaling and breast cancer and provide an overview of existing mechanisms, challenges, and potential opportunities for advancing the therapy and diagnosis of breast cancer.


Breast cancer was the most commonly diagnosed cancer (24.2% of the total cancer cases) and the leading cause of cancer-related death (15% of the total cancer deaths) among females worldwide in 2018 [1]. Metastatic disease accounts for more than 90% of breast cancer-related deaths [2]. Increasing evidence suggests that the genetic mutation-driven activation of Wnt signaling is the key factor in breast cancer metastasis [3].

Wnt signaling is an evolutionarily conserved pathway in metazoan animals [4]. The name ‘Wnt’ is a fusion of the name of the vertebrate homolog Integrated (Int-1) [5, 6] and the name of the Drosophila segment polarity gene Wingless [7, 8]. It has been almost four decades since the discovery of the Int-1 proto-oncogene, now known as Wnt-1, which was identified as an integration site for mouse mammary tumor virus (MMTV) [5]. Breast cancer, on the other hand, is the first cancer to be associated with Wnt signaling.

In recent decades, a growing number of studies have demonstrated that Wnt signaling involves the proliferation [9], metastasis [3, 10, 11], immune microenvironment regulation [3, 12], stemness maintenance [13], therapeutic resistance [14], and phenotype shaping [15, 16] of breast cancer. Various Wnt signaling inhibitors that act on different targets have been developed, and many of them exhibit potent anticancer potential [17]. However, no Wnt inhibitors have been approved for breast cancer treatment to date.

This review describes the three well-established Wnt signaling pathways, summarizes the main findings between Wnt signaling and breast cancer based on biological mechanisms, elaborates the challenges in drugging Wnt signaling, and provides potential solutions for both basic research and the clinical treatment of breast cancer.

An overview of the Wnt signaling pathway

There are 19 Wnt genes in the human genome, all of which encode secreted lipoglycoproteins that have fundamental roles in controlling cell specification, cell-cell interactions, stem cell self-renewal, and tissue patterning during embryonic development [18, 19]. Wnt proteins (Wnts) couple to various receptors and thereby activate different downstream pathways [20]. Canonical Wnt signaling is a β-Catenin-dependent and T cell factor (TCF)/lymphoid enhancer factor (LEF)-involved pathway that is responsible mainly for breast cancer cell proliferation and ‘stemness’ maintenance [21]. Increasing evidence indicates that Wnt–PCP and Wnt–Ca2+ signaling, the two well-established β-Catenin-independent noncanonical Wnt pathways, are responsible for breast cancer cell metastasis [22, 23]. The processes of immune microenvironment regulation, therapeutic resistance, and phenotype shaping of breast cancer seem complicated and are always mediated by cooperation and crosstalk between canonical and noncanonical Wnt pathways.

Canonical Wnt signaling pathway

Canonical Wnt signaling (also known as Wnt/β-Catenin signaling) is the best-characterized pathway and is generally triggered by Wnt1, Wnt2, Wnt3, Wnt3a, Wnt8b, Wnt10a, Wnt10b, and so on (Table 1) [18, 19, 79]. In the endoplasmic reticulum (ER), the conserved cysteine of Wnts is palmitoylated by Porcupine to a lipid-bound form that is also an active form [80]. The ER-to-Golgi trafficking of Wnts is mediated by the p24 protein family (such as TMED2/CHOp24, TMED4/éclair, and TMED5/opossum) [81,82,83]. Then, lipid-modified Wnts are transported by GPR177 (also known as Wntless/Evenness/Interrupted/Sprinter) [84,85,86,87] in an endosome-dependent manner [88,89,90] and secreted into the extracellular matrix using exosomes as potent carriers [10, 91,92,93]. Notum is a deacetylase that acts as a lipid eraser of Wnts and can inactivate Wnts [94, 95].

Table 1 Wnt ligands and related factors in breast cancer

Frizzleds (Fzds) are 7-transmembrane (7-TM) proteins that act as the primary receptors for Wnts [96,97,98], while low-density lipoprotein receptor-related proteins (LRPs) are single-pass transmembrane proteins that act as coreceptors for Fzds [99,100,101]. Wnt signaling is inhibited by endogenous inhibitors, such as Wnt inhibitory factor 1 (WIF-1) [102], Cerberus [103], and secreted Fzd-related proteins (sFRPs) [104] that interact with Wnts directly, Wise/SOST [105,106,107] and dickkopf proteins (Dkks) [108, 109] that bind to LRPs and block Fzds–LRP heterodimer formation, and insulin-like growth factor-binding protein 4 (IGFBP4) physically interacts with Fzd8 and LRP6 and inhibits Wnt3a binding [110]. Of note, sFRPs can also interact with Fzds and inhibit Wnt signaling [111, 112]. Additionally, Rnf43 and Znrf3 are two single-pass transmembrane E3 ligases that specifically mediate the multiubiquitination of Fzds [113, 114].

Wnt signaling is maintained in an off state in the absence of extracellular Wnts. β-Catenin is the core component of canonical Wnt signaling and binds to the cytoplasmic tail of E-cadherin for cell-cell adhesion [115,116,117,118]. In the cytoplasm, β-Catenin is hijacked by the ‘destruction complex’, which comprises adenomatous polyposis coli (APC) [119, 120], Axin [121,122,123,124], glycogen synthase kinase 3β (GSK-3β) [125, 126], casein kinase 1α (CK1α) [127, 128], protein phosphatase 2A (PP2A) [129], and Wilms tumor gene on X chromosome (WTX) [130], thereby being ubiquitinated by the Skp1, Cullin1 and F-box protein β-TrCP (SCFβ-TrCP) ubiquitin ligase and degraded [131, 132]. β-Catenin is first phosphorylated by CK1α at Ser45, followed by GSK-3β phosphorylation at the Thr41, Ser37, and Ser33 residues [90]. The phosphorylation of Ser33 and Ser37 creates the recognition site for β-TrCP [127] for subsequent degradation. Tankyrase 1/2 (TNKS1/2) destabilizes Axin, making it an attractive target for Wnt signaling regulation [133]. In addition, Siah-1 interacts with APC and promotes the degradation of β-Catenin independent of GSK-3β-mediated phosphorylation and β-TrCP-mediated ubiquitin [134].

In the nucleus, TCF [135, 136] and C-terminal binding protein (CTBP) [137] interact with Transducin-like enhancer/Groucho (TLE/GRG), while histone deacetylases (HDACs) interact with TCF and LEF1 [138, 139]. These proteins form a repressor complex that represses the expression of Wnt target genes [140]. In addition, β-Catenin is inhibited from binding to TCF/LEF by inhibitors of β-Catenin and TCF (ICAT) [141] and Chibby (CBY) [142].

The canonical Wnt signaling cascade is initiated from the binding of lipid-modified Wnts to the receptor complex. Norrin binds to Fzd4 and activates the canonical Wnt pathway, although it is structurally unrelated to Wnts [143,144,145]. On the other hand, R-spondin binds to leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) and induces the membrane clearance of Rnf43/Znrf3, which removes the ubiquitylation of Fzd4 [113, 114]. LRP6 is phosphorylated by GSK-3 and CK1 [146, 147], which recruits the scaffold protein Axin [148], while Fzds recruit Dishevelled (Dvl) [149] to the plasma membrane, thereby disrupting the destruction complex [150].

β-Catenin is phosphorylated at Ser191 and Ser605 by Jun N-terminal kinase 2 (JNK2), which facilitates its nuclear localization mediated by Rac1 [151]. In the nucleus, β-Catenin serves as a scaffold for the LEF [152, 153] and TCF [154,155,156] families, recruiting coactivators such as CREB-binding protein (CBP)/p300 [157], Pygopus (PYGO) and B cell lymphoma 9 (BCL9) [158, 159] and leading to the transcription of a large set of target genes (Fig. 1).

Fig. 1

Canonical Wnt signaling pathway in mammals

Wnt–PCP signaling pathway

Wnt–PCP signaling does not involve β-Catenin, LRP, or TCF molecules and is generally triggered by Wnt4, Wnt5a, Wnt5b, Wnt7b, and Wnt11 [160,161,162] (Table 1). These Wnts can also be inhibited by directly binding to endogenous inhibitors, including sFRPs, WIF, and Cerberus, and sFRPs may also inhibit Wnt–PCP signaling by binding to Fzds [163].

The complementary and mutually exclusive distribution of transmembrane complexes is the key feature of planar polarization, which results in the asymmetric enrichment of proximal and distal transmembrane complexes in cells (Fig. 2a). The proximal transmembrane complex is composed of Vang-like 2 (Vangl2), cadherin EGF LAG seven-pass G-type receptor 1 (Celsr1), Prickle, inturned (Intu) and Dvl [164], while the distal transmembrane complex is composed of Fzds, Celsr1, Inversin (Invs) and Dvl. On the proximal side, Vangl2 recruits Prickle, which competes with Invs for Dvl binding and therefore disrupts the localization of Invs towards the proximal side. Intriguingly, noncanonical Wnt binding to Fzds leads to Dvl phosphorylation and distal side localization of the Invs [165] and Dvl–Par6 complex, and Smurf is recruited by phosphorylated Dvl to Par6, thereby ubiquitinating and degrading Par6-bound Prickle on the distal side and antagonizing the inhibitory action of Prickle on Wnt–PCP signaling [166] (Fig. 2b). This asymmetric cell patterning, in turn, directs the orientation of subcellular structures and cell behaviors through the regulation of cytoskeletal elements and cellular adhesions [161].

Fig. 2

Wnt–PCP signaling pathway in mammals. a Planar cell polarity of the asymmetric transmembrane complexes. b Asymmetric PCP signaling components form transmembrane complexes. c Wnt–PCP signaling pathway in mammals

Fzds [167,168,169,170], Celsr1 [171,172,173], and Vangl2 [174,175,176,177,178,179] are core receptors in Wnt–PCP signaling. Fzds are still the primary receptors for Wnts, while receptor-like tyrosine kinase (RYK) [180], muscle-skeletal receptor Tyr kinase (MUSK) [181,182,183], protein tyrosine kinase 7 (PTK7) [184], receptor Tyr kinase-like orphan receptor 1/2 (ROR1/2) [162], Syndecan [185, 186] and Glypican [187] act as coreceptors for Fzds. However, the ligand-receptor binding interaction between Wnts and Celsr1 [188] or Vangl2 [189] has not been clarified to date.

The formation of the Fzds–Celsr1–Invs–Dvl complex and the interaction between Dvl and Dvl-associated activator of morphogenesis (DAAM) activate the small GTPases Rac1 [190] and Ras homologue gene-family member A (RHOA) [191, 192]. Rac1 activates JNK [193], which further phosphorylates c-Jun at Ser63 and Ser73, thereby activating c-Jun [194]. RHOA subsequently activates diaphanous 1 (DIA1) and RHO-associated coiled-coil-containing protein kinase (ROCK) [195]. Then, JNK activates CapZ-interacting protein (CapZIP) [196], ROCK activates mitogen-activated protein kinase (MRLC) [197], and DAAM activates Profilin [198]. These PCP effectors lead to the development of lateral asymmetry in epithelial sheets and other structures [199], as well as cell polarity and migration by remodeling the cytoskeleton [200] (Fig. 2c).

Wnt–Ca2+ signaling pathway

Wnt–Ca2+ signaling is a less focused noncanonical Wnt pathway but plays a central role in cell fate during early embryogenesis [201], cancer progression [202,203,204], interneural communication [205], the inflammatory response [206], and so on. Wnt–Ca2+ signaling is initiated mostly by Wnt5a and Fzd2, and pertussis toxin-sensitive heterotrimeric G protein subunits [207] are required for the activation of phospholipase C (PLC). Activated PLC cleaves phosphatidylinositol-4,5-bisphosphate (PtdInsP2), a membrane-bound inositol lipid, into diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (InsP3). DAG, together with Ca2+, activates protein kinase C (PKC), which further stimulates cell-division cycle 42 (Cdc42) and promotes actin polymerization. On the other hand, InsP3 binds to inositol-1,4,5-trisphosphate receptors (InsP3Rs) [208] on the ER membrane, opening calcium channels for Ca2+ release and increasing cytoplasmic Ca2+ levels [209]. The decrease in Ca2+ levels within the ER lumen is sensed by stromal interaction molecule 1/2 (STIM1/2), which gains an extended conformation to trap and activate ORAI proteins at the plasma membrane and induce store-operated Ca2+ entry (SOCE) [210, 211]. In addition, sarcoplasmic/ER Ca2+ ATPases (SERCAs) act as Ca2+ ion pumps that pump Ca2+ from the cytosol to the ER. An increased Ca2+ concentration activates the phosphatase calcineurin and several calcium-dependent kinases, including PKC and calcium calmodulin mediated kinase II (CAMKII). The increased activity of calcineurin, in turn, activates the nuclear factor of activated T cells (NFAT) [212]. In contrast, CAMKII stimulation activates TGFβ-activated protein kinase 1 (TAK1), which subsequently activates nemo-like kinase (NLK), resulting in the phosphorylation of TCF and the inhibition of β-Catenin/TCF signaling [213, 214]. The Wnt–Fzd–Dvl complex also activates cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase 6 (PDE6), thereby depleting cellular cGMP and inactivating protein kinase G (PKG), which in turn increases the cellular concentration of Ca2+. The G protein-induced activation of p38 via mitogen-activated protein kinase 3/6 (MKK3/6) is required for the activation of PDE6. Moreover, the p38-induced phosphorylation of activating transcription factor 2 (ATF2) on Thr69 and Thr71 is important for its transcription [215, 216] (Fig. 3).

Fig. 3

Wnt–Ca2+ signaling pathway in mammals

Wnt signaling alterations in breast cancer

Numerous studies have shown that the constitutive components of Wnt signaling are altered in breast cancer cells. These alterations include mutations, amplifications, deletions, and methylations that occur at the DNA level, posttranscriptional modifications that occur at the mRNA level, and posttranslational modifications that occur at the protein level. These alterations also include changes in subcellular localization, especially for β-Catenin. Mutation of CTNNB1, which encodes β-Catenin, is rare in breast cancer [217]. However, the activation of Wnt signaling is nonetheless thought to play an essential role in breast tumorigenesis [69]. This is mainly due to the epigenetic activation of Wnts and the inactivation of Wnt inhibitors (Table 1). Nonetheless, it has been reported that Wnt5a is lost in breast cancer [75, 218,219,220]. Foxy-5, a Wnt5a mimicking hexapeptide, impairs the migration and invasion of breast cancer without affecting apoptosis or proliferation by reconstituting Wnt5a signaling [221] and has entered phase I clinical trials (NCT02020291 and NCT02655952) for metastatic breast, colorectal and prostate cancer treatment and a phase II clinical trial (NCT03883802) for Wnt5a-low colon cancer neoadjuvant therapy. In addition, most canonical and noncanonical Wnt receptors are elevated in breast cancer, especially in triple-negative breast cancer (TNBC) and basal-like breast cancer (BLBC). E-cadherin, as an interacting protein of β-Catenin, is frequently mutated or silenced in BLBC and TNBC, which leads to the release of β-Catenin from the cytomembrane into the cytoplasm [222,223,224] (Table 2).

Table 2 Wnt receptors and coreceptors in breast cancer

Cytoplasmic β-Catenin should be carefully controlled by the destruction complex in the cytoplasm. However, the destruction complex components are frequently mutated, deleted, hypermethylated, or reduced in breast cancer, which increases the stability of cytoplasmic β-Catenin and the probability of β-Catenin entering the nucleus. Most coactivators are highly expressed in breast cancer, as expected. However, it is interesting that some corepressors (e.g., TLE/GRG and CTBP) are elevated in breast cancer [254, 255] (Table 3). These studies suggest that the activation of canonical Wnt signaling in breast cancer is induced mainly by epigenetic alterations in the constitutive components rather than the mutation of β-Catenin or APC. Noncanonical Wnt signaling is preferentially activated in TNBC/BLBC and is induced mainly by the epigenetic activation of noncanonical Wnts and their receptors (Tables 1 & 2). Cytoplasmic components of noncanonical Wnt signaling are commonly involved in various signaling pathways and are challenging to define as exclusive components of noncanonical Wnt signaling (Figs. 2 & 3).

Table 3 β-Catenin and its related factors in breast cancer

Wnt signaling in breast cancer classification

Invasive ductal carcinoma no-special-type (IDC-NST) and invasive lobular carcinoma (ILC) are the most common histological subtypes of breast carcinoma, accounting for 70 ~ 75% and 10 ~ 14%, respectively [272]. β-Catenin expression is significantly correlated with histological type. The majority of IDCs display a regular pattern of β-Catenin expression, with membranous expression (80.6%) and nuclear expression (12.5%), whereas ILCs lack membranous expression (14.7%) and nuclear expression (0%) [256]. Additionally, E-cadherin and β-Catenin expression is largely preserved in ductal carcinoma in situ (DCIS) [273]. However, lobular carcinoma in situ (LCIS) shows the simultaneous loss of E-cadherin and β-Catenin expression [274]. This may explain why IDCs have a worse prognosis than ILCs [275] (Fig. 4a).

Fig. 4

Wnt signaling in breast cancer classification. a Wnt signaling in the histological classification of breast cancer. b Wnt signaling in the molecular classification of breast cancer. (adapted from [272], additional data are based on an open-source database:

Furthermore, breast cancer can be classified into five intrinsic subtypes: luminal A, luminal B, Her-2 enriched, normal-like, and BLBC [276,277,278]. However, the normal-like subtype is controversial, potentially due to normal tissue contamination and low tumor cellularity [279]. Claudin-low was initially considered a breast cancer subtype [280, 281] and later redefined as a breast cancer phenotype [282].

Surrogate intrinsic subtypes are based on the immunohistochemistry of estrogen receptor (EsR), progesterone receptor (PgR), human epidermal growth factor receptor 2 (Her-2), and Ki67 and consist of luminal A-like, luminal B-like, Her-2 enriched, and TNBC [283]. The majority of BLBCs and claudin-low intrinsic subtypes are TNBCs [272, 284]. TNBCs can be further divided into basal-like 1 (BL-1), basal-like 2 (BL-2), immunomodulatory (IM), luminal androgen receptor (LAR), mesenchymal (M), and mesenchymal stem-like (MSL) [285].

The claudin-low subtype is composed mostly of the M and MSL subtypes of TNBC [286], which, together with the BL-2 subtype of TNBC, are linked to Wnt signaling activation [285]. Intriguingly, the majority of claudin-low cancers are metaplastic breast cancers [281]. This is consistent with the previous description that Wnt signaling activation is enriched in metaplastic breast cancers [287], BLBCs [257], and TNBCs [256]. Specifically, Wnt signaling activation in metaplastic breast cancers is caused mainly by genetic changes, such as CTNNB1 and APC mutations [287], whereas Wnt signaling activation in BLBCs and TNBCs is associated mainly with the strong expression of nuclear β-Catenin [256, 257]. This may be the main reason for the worst prognosis of TNBCs among all subtypes. Notably, both basal and luminal tumor cells are found in MMTV-Wnt1 mammary tumors, implying that they are derived from a bipotent malignant progenitor cell [24, 288]. Based on these studies, Wnt signaling is the critical pathway for phenotype shaping in both histological subtypes and molecular subtypes of breast cancer (Fig. 4 b).

Wnt signaling in the breast cancer immune microenvironment

All breast cancers arise in the terminal duct lobular units (the functional unit of the breast) of the collecting duct [272] (Fig. 5 a). Breast cancer cells commonly reside in a complicated tumor microenvironment that is composed mainly of genetically abnormal cells surrounded by blood vessels, fibroblasts, immune cells, stem cells and the extracellular matrix (ECM), and dynamic crosstalk among these various components ultimately determines the fate of breast cancer [289] (Fig. 5 b).

Fig. 5

Wnt signaling in the immune microenvironment of breast cancer. a Schematic representation of the human mammary gland, breast cancer, and an enlarged cross-section of the duct (adapted from [272]). b Tumor microenvironment of breast cancer. c Wnt signaling in the immune microenvironment of breast cancer

The reciprocal crosstalk between breast cancer cells and immune cells is initiated by the neoantigens [272] that arise from nonsynonymous mutations and other genetic alterations [290]. These neoantigens are presented by antigen-presenting cells (APCs) on major histocompatibility complex class I (MHC I) or MHC II molecules [272], resulting in the activation of CD8+ (cytotoxic) [291] and CD4+ (helper) T cells [292]. Activated CD8+ T cells directly induce premalignant breast cell lysis by releasing cytolytic perforin and granzyme B [293] and promote the apoptosis of premalignant breast cells by expressing Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL) on their cell surface [272, 294]. This may explain why high breast tumor-infiltrating CD8+ T cell counts are associated with improved clinical outcomes [295]. CD4+ TH1 cells arise from naive T cells that are activated by interleukin (IL)-12 (provided by dendritic cells and macrophages) and interferon (IFN)-γ (provided by natural killer (NK) cells) [296] and amplify the anticancer effect of CD8+ T cells by secreting IFN-γ, IL-2, and tumor necrosis factor (TNF)-α. NK T cells recognize MHC I-like molecule CD1d on dendritic cells and are further activated by IL-12 that is expressed by dendritic cells. Activated NK T cells also recognize CD1d expressed by breast cancer cells [297] and recruit NK cells by releasing IFN-γ, which kills breast cancer cells directly (Fig. 5 c).

However, Wnt/β-catenin signaling activation suppresses the antitumor immune response [298]. Malignant breast cells with activated Wnt signaling develop several strategies to avoid immune recognition and destruction. They express CD24 [299] and CD47 [300,301,302] as ‘don’t eat me’ signals to prevent phagocytosis from macrophages by interacting with Siglec-10 and SIRP-α, respectively, expressed by macrophages. Remarkably, CD24 is a direct target of Wnt1 in breast cancer [303], while CD47 is an indirect target of Wnt signaling mediated by SNAI1 and ZEB1 in breast cancer [304]. In addition, CD47 and programmed death-ligand 1 (PD-L1) are controlled by Myc, a well-documented target of Wnt/β-catenin signaling [305]. In addition, TNBCs upregulate PD-L1 through Wnt signaling activity, thereby blocking CD8+ T cell activation [306]. Cytotoxic T lymphocyte antigen 4 (CTLA-4) is expressed at a low level in naive T cells but is rapidly induced after activation. Coincidentally, CTLA-4 is also a direct target of Wnt/β-catenin signaling [307]. Tumor-associated macrophages (TAMs) [308] and forkhead box protein P3 (FoxP3)+ Treg cells [309,310,311] are commonly associated with a poor clinical outcome. TAMs directly inhibit T cell functions by expressing checkpoint ligands (such as PD-L1, PD-L2, B7–1/CD80, and B7–2/CD86) [312] and inhibit CD4+ TH1, TH2, and CD8+ T cells by secreting immunosuppressive cytokines (such as IL-10 and TGFβ) [313]. TAMs also inhibit cytotoxic T cells by releasing arginase 1 and indoleamine 2,3-dioxygenase (IDO). In addition, TAMs secrete Wnt7b, which mediates the angiogenic switch and metastasis in breast cancer [46]. FoxP3+ Treg cells exert their immunosuppressive effect by consuming IL-2, secreting immunosuppressive cytokines (such as IL-10, IL-35, and TGFβ), converting ATP into adenosine, and secreting perforin and/or granzyme B, thereby limiting, inhibiting or destroying effector cells and attenuating the functions of APCs mediated by CTLA-4 [314]. Intriguingly, TAMs and FoxP3+ Treg cells express IL-10 and TGFβ, which induces reciprocal activation. Based on these studies, atezolizumab, an anti-PD-L1 monoclonal antibody, has been approved by the Food and Drug Administration (FDA) for advanced or metastatic TNBC with PD-L1 expression [315]. T cell exhaustion mediated by Wnt signaling is a strategy that was developed for the immune escape of malignant breast cells (Fig. 5 d).

TP53 is the most frequently altered gene in metastatic breast cancers [316]. The loss of TP53 in breast cancer cells triggers the secretion of Wnt1, Wnt6, and Wnt7a. These Wnts bind to Fzd7 and Fzd9 on the surface of TAMs, stimulating TAMs to produce IL-1β [3]. IL-1β elicits IL-17 expression from γδ T cells, resulting in the systemic, granulocyte colony-stimulating factor (G-CSF)-dependent expansion and polarization of neutrophils. Phenotypically altered neutrophils produce inducible nitric oxide synthase (iNOS), which suppresses the activity of antitumor CD8+ T cells and thereby induces systemic inflammation and drives breast cancer metastasis [317]. FoxP3+ Treg cells express receptor activator of nuclear factor-κB (RANK) ligand (RANKL), which stimulates the pulmonary metastasis of RANK+ breast cancer cells [318]. Cancer-associated fibroblasts (CAFs) promote tumor immunosuppression by releasing IL-6, which increases the number of FoxP3+ Treg cells [319]. Malignant breast cells acquire invasive properties and become invasive breast cancer cells through an epithelial-mesenchymal transition (EMT)-dependent process that is mediated mostly by the Wnt signaling pathway [320,321,322,323] (see below). FoxP3+ Treg cells and invasive breast cancer cells secrete matrix metalloproteinases (MMPs) and vascular endothelial growth factors (VEGFs) to degrade the ECM and promote angiogenesis, resulting in breast cancer metastasis (Fig. 5 e). Of note, MMPs and VEGFs are classic targets of Wnt signaling [324]. Collectively, these findings show that Wnt-driven systemic inflammation and the immunosuppressive niche provide an immune microenvironment for breast cancer metastasis.

Wnt signaling in the EMT-dependent metastasis of breast cancer

The immune microenvironment is an external factor in breast cancer metastasis, while genetic alteration-driven cell transformation is the internal factor in breast cancer metastasis [325]. Increasing evidence suggests that EMT contributes to the primary cause of breast cancer metastasis, especially for BLBCs [326]. The term EMT refers to a complicated and highly regulated molecular and cellular process by which epithelial cells shed their differentiated characteristics and acquire mesenchymal features [327]. Snai1 (Snail), Snai2 (Slug), Twist1, ZEB1, and ZEB2 (also known as Sip-1 and Zfhx1b) are core EMT transcription factors (EMT-TFs) [328]. These core EMT-TFs are mechanically activated by TGFβ–Smads, Wnt/β-Catenin signaling, epidermal growth factor (EGF)/fibroblast growth factor (FGF)–receptor tyrosine kinase (RTK) signaling, Notch signaling, and the MAPK pathway, further initiating EMT-associated changes in gene expression, such as the suppression of E-cadherin and ZO-1 and the activation of N-Cadherin, MMPs, integrins, and fibronectin [329].

The overexpression of core EMT-TFs has been observed in primary invasive breast cancer and is usually associated with a poor prognosis [327, 330,331,332,333]. Specifically, Snail [224], Slug [16, 334], Twist1 [15], ZEB1, and ZEB2 [333] are commonly overexpressed in BLBCs. While Snail [322, 331], Slug [321], Twist1 [335], and ZEB1 [336] are direct targets of Wnt/β-Catenin signaling in breast cancer, ZEB2 is inclined to be an upstream factor of Wnt/β-Catenin signaling [337, 338]. Twist1, ZEB1, and ZEB2 are also induced by the MAPK pathway and may be mediated through TGFβ and noncanonical Wnt signaling [329] (Fig. 6). Overexpressed EMT-TFs suppress the expression of E-cadherin, leading to the release of β-Catenin from the cytomembrane into the cytoplasm (Fig. 1). Free β-Catenin, in turn, promotes the expression of EMT-TFs, thereby forming a positive feedback loop. In addition, Wnt5a/b and Fzd2 drive EMT through a noncanonical Wnt pathway that includes Fyn and Stat3 [22]. The early dissemination and metastasis of Her-2+ breast cancer are also driven by the noncanonical Wnt (Wnt5a, Wnt5b, and Wnt11)-dependent EMT-like pathway [11]. Wnt-driven EMT-TF expression further regulates the morphogenesis of breast cancer cells [341] (such as the formation of lamellipodia [342]) and directly secretes MMPs, thereby acquiring migratory and invasive properties. Indeed, EMT also contributes to chemoresistance [343], stem cell properties [344], and immunosuppression [345].

Fig. 6

Wnt signaling in the EMT-dependent metastasis of breast cancer. (adapted from [329, 339, 340])

Wnt signaling in the inter- and intratumoral heterogeneity of breast cancer

Extensive molecular and cellular heterogeneity exists in human breast cancer tissues [312, 346] and determines the diversity of pathological features, prognoses, and responses to available therapy [347]. The heterogeneity of breast cancer involves complicated concepts, termed intertumoral heterogeneity (tumors from different patients), mammary epithelial differentiation hierarchy, intertumoral heterogeneity (within a single tumor), and breast cancer stem cells (BCSCs) [348].

The intertumoral heterogeneity of breast cancer can be explained by a mammary epithelial differentiation hierarchy theory by which different mammary epithelial cell subpopulations that reside in mammary ducts provide a repertoire for intertumoral heterogeneity. Two hypothetical models of mammary epithelial differentiation hierarchy have been established based on gene expression profiling, and the difference lies in whether adult quiescent mammary stem cells (MaSCs) exist [349]. Cumulative evidence indicates that adult bipotent or multipotent quiescent MaSCs, such as LGR5+Tspan8high MaSCs [350], may reside within the adult mammary gland [351, 352].

Wnt signaling executes cardinal roles in maintaining the phenotype of MaSCs [349]. Mouse MaSCs are identified by the surface marker LinCD24+CD29high subpopulation, which is expanded in MMTV-Wnt1-induced premalignant mammary tissue [353]. On the other hand, human stem-like cells identified by the surface marker LinCD10CD24ProCr+CD44+ subpopulation have been identified in both normal human mammary epithelium and breast carcinomas [21]. Notably, both protein C receptor (ProCr) and CD44 are targets of Wnt/β-catenin signaling [21, 354]. LRG5 is not only a coreceptor (Fig. 1) but also a target of Wnt/β-catenin signaling [355]. LRG5+ mammary epithelial cells contribute to the reconstitution of an entire mammary gland, suggesting that LRG5 is a potent biomarker of MaSCs [356]. MMP3, as an extracellular regulator of the Wnt signaling pathway, is necessary for the phenotype and activity maintenance of MaSCs [41]. Axin2 is not only a target but also a negative feedback regulator of Wnt signaling (Fig. 1) and is therefore sensitized to Wnt signals. The Wnt-responsive cell population with Axin2+ is enriched for MaSCs in the adult mammary gland [357, 358]. In addition, the macrophages that receive the Notch pathway ligand Dll1 from MaSCs, together with Gli2+ stromal cells, govern MaSCs by secreting Wnts and other paracrine factors [359, 360]. These data demonstrate that Wnt signaling is essential for MaSCs to maintain their phenotype and self-renewal.

A comparison of the gene signatures between normal mammary epithelial subpopulations and breast cancer subtypes implied that the claudin-low cancer subtype is remarkably similar to LGR5+Tspan8high MaSCs [349, 350]. In contrast, the basal-like cancer subtype shares great similarity to the luminal progenitor subpopulation [361, 362]. The Her-2+, luminal B, and luminal A cancer subtypes reflect different cell subtypes within the luminal lineage and in turn gradually lose differentiation capacity. Therefore, the luminal A subtype is closest to mature luminal cells, while the Her-2+ and luminal B subtypes likely originate in cells restricted to the luminal lineage [349]. These findings suggest a hypothesis that various breast cancer subtypes (intertumoral heterogeneity) are derived from different mammary epithelial cell subpopulations [363] (Fig. 7). Although Wnt signaling controls various aspects of mammary gland development and differentiation during both embryogenesis and postnatal life [358], this hypothesis is derived from the conjecture of comparative genomics rather than facts. More sophisticated lineage tracing systems may be required to address this question in the future.

Fig. 7

Wnt signaling in the inter- and intratumoral heterogeneity of breast cancer. (adapted from [349])

Two models have been proposed to account for the intratumoral heterogeneity of breast cancer. The clonal evolution model explains intratumor heterogeneity as a result of natural selection and uses stochastic mutations as a platform. Advantageous clones differ in time and space within an individual tumor and thereby contribute to the intratumoral heterogeneity of breast cancer [348]. The cancer stem cell model hypothesizes that the intratumoral heterogeneity is derived from common malignant self-renewing cells that can generate the full repertoire of tumor cells (i.e., BCSCs). BCSCs are hypothesized to be breast cancer-initiating cells (BCICs) that undergo a second oncogenic event by which BCSCs gain the ability of sustained propagation, whereas BCICs are hypothesized to be MaSCs that undergo one oncogenic event [364]. BCSCs were initially identified by surface markers as LinCD44+CD24−/low [365]. Subsequently, an aldehyde dehydrogenase 1 (ALDH1)+ BCSC population capable of self-renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor was identified [366]. Of note, a portion of LinCD44+CD24−/low BCSCs overlap with ALDH1+ BCSCs, and LinCD44+CD24−/lowALDH1+ BCSCs display a more tumorigenic feature [366] (Fig. 7).

Wnt signaling is critical not only to the phenotypic maintenance of BCSCs but also to MaSC–BCSC transformation. CD44 is a well-known target of Wnt/β-catenin signaling and contributes the ‘stemness’ properties to BCSCs [21]. The depletion of CD44 effectively prevents aggregation, blocks lung metastasis, and impairs the ‘stemness’ of circulating breast tumor cells [367]. ProCr is another target of Wnt/β-catenin signaling, and ProCr+ MaSCs represent one of the origins of BCSCs [354]. Intriguingly, 100% of CD44+ breast tumor cells are positive for ProCr [21]. Indeed, the expression level of CD44 is also controlled by noncanonical Wnt5a [15] and Wnt5b [16]. As discussed above, ALDH1+ BCSCs represent another important subpopulation of BCSCs [366]. ALDH1 is not a direct target of Wnt/β-catenin signaling; however, its activity is controlled by syndecan-1, a coreceptor of noncanonical Wnt–PCP signaling (Fig. 2 c), and the BCSC phenotype that is characterized by ALDH1 activity and CD44+CD24−/low is reduced upon Syndecan-1 knockdown [248]. These findings suggest that the phenotypic maintenance of BCSCs is governed jointly by both canonical and noncanonical Wnt signaling.

The constitutive overexpression of Wnt1 in the mammary gland directly gives rise to tumors [5], suggesting that Wnt signaling activation is an independent oncogenic event. MMTV-Wnt1- and MMTV-ΔN89β-Catenin-induced tumors contain differentiated cells of both luminal and basal lineages, suggesting that the precursor of Wnt1- and ΔN89β-Catenin-induced tumors is a bipotential stem cell [24, 368]. The loss of Pten accelerates the dysregulation of this subpopulation during tumor initiation [288]. Intriguingly, MMP3, as a regulator of Wnt signaling, maintains the phenotype of MaSCs on one side [41] and promotes mammary carcinogenesis on the other [369]. Additionally, the LinCD24+CD29high MaSC subpopulation is expanded in MMTV-Wnt1-induced premalignant mammary tissue [353]. These findings indicate that Wnt signaling is the principal driver in MaSC–BCSC transformation. However, the relationship between Wnt1/ΔN89β-Catenin-induced bipotential stem cells and LinCD44+CD24−/low or ALDH1+ BCSCs remains obscure (Fig. 7).

Wnt signaling in breast cancer drug resistance

Drug resistance in cancer is considered to be a multifaceted problem involving tumoral heterogeneity, drug efflux/inactivation, survival pathway activation, etc. [370]. The Goldie-Coldman hypothesis explains drug resistance as a result of directed selection and uses heterogeneous tumor cell clones with various mutations as a platform [371, 372]. Drug-resistant clones survive and expand under toxic drug stress; on the other hand, Wnt signaling inactivation causes BCSCs to enter a quiescent state that is insensitive to drugs [352, 373], thereby leading to multidrug resistance. The Wnt signaling-mediated mammary epithelial differentiation hierarchy and the formation and self-renewal of BCSCs are drivers of the tumoral heterogeneity of breast cancer (Fig. 8 a).

Fig. 8

Wnt signaling in breast cancer drug resistance. a Wnt signaling-induced tumoral heterogeneity involves the drug resistance of breast cancer. b The APC transporters P-gp (encoded by ABCB1) and BCRP (encoded by ABCG2), which are involved in drug efflux, are targets of Wnt signaling in breast cancer. c Wnt signaling involves endocrine resistance in breast cancer. The thickness of the arrow represents the relative contribution of each pathway to the overall oxidation of tamoxifen (adapted from [374])

Drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters is another vital pathway in the drug resistance of breast cancer. P-glycoprotein (P-gp, also known as MDR1, encoded by ABCB1), multidrug resistance protein 1–5 (MRP1–5, encoded by ABCC1–5), and breast cancer resistance protein (BCRP, encoded by ABCG2) are well-defined ABC transporters that are involved in the transport of clinically relevant drugs [375]. PYGO2 is a coactivator in Wnt/β-catenin signaling (Fig. 1) that mediates chemoresistance by activating MDR1 expression in breast cancer [376]. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas [377, 378] and promotes drug resistance by increasing ABCG2 expression in a Wnt/β-catenin signaling-dependent manner [379, 380] (Fig. 8 b).

EsR-positive breast cancers account for nearly 80% of all breast cancer cases [1], and approximately 50% of mortalities arise from EsR-positive breast tumors [381]. EsR is a ligand-inducible transcription factor that contains a central DNA binding domain, an intrinsically disordered N-terminal activation function 1 (AF1) domain, and a C-terminal ligand-binding domain (LBD) [381]. Tamoxifen was the first clinically approved EsR-targeted drug and competes with 17β-estradiol (E2) for EsR binding and prevents LBD-mediated coactivator recruitment, thereby impairing the transcriptional activity of EsR [381]. The primary (4-hydroxytamoxifen) and secondary (endoxifen) metabolites of tamoxifen mediated by the cytochrome P450 system are more potent than tamoxifen itself [374]. Cytochrome P450 2D6 (CYP2D6) is undoubtedly the key enzyme for endoxifen generation. One-third of women treated with tamoxifen for 5 years experience recurrence within 15 years, and endocrine-resistant disease may account for 25% of all breast cancers [382]. Inactive CYP2D6 that fails to convert tamoxifen to endoxifen and the lack of ERα expression are primary mechanisms of endocrine resistance [383]. Intriguingly, both canonical and noncanonical Wnt signaling pathways are activated in tamoxifen-resistant breast cancer cells, and Wnt3a increases the resistance of EsR+ breast cancer cells to tamoxifen treatment [384]. Furthermore, Sox2 is increased in tamoxifen-resistant breast cancer cells and negatively correlated with ERα expression. Sox2 also maintains the phenotype of breast cancer stem/progenitor cells by activating Wnt signaling, thereby rendering EsR+ breast cancer cells insensitive to tamoxifen treatment [14]. Although there is no direct evidence to prove the relationship between Wnt signaling and CYP2D6 activity or tamoxifen metabolism, some studies indicate that such a relationship may exist. Endoxifen levels are 20% lower during winter months than return to mean levels across seasons and are associated with low vitamin D3 levels; thus, vitamin D3 may maintain endoxifen levels by increasing CYP2D6 activity [385]. Indeed, vitamin D3 can regulate intestinal CYP3A4 expression through the binding of the vitamin D receptor (VDR)-retinoid X receptor (RXR) heterodimer to the ER6 motif of the CYP3A4 promoter [386, 387]. On the other hand, vitamin D3 increases tamoxifen sensitivity by inhibiting Wnt/β-catenin signaling [388] (Fig. 8 c). Of note, vitamin D3 has been proven to be a potent disruptor of β-Catenin/TCF [389, 390]. Endoxifen is also a substrate of the efflux transporter MDR1 [391], a target of Wnt signaling, as we discussed above [376]. These findings indicate that Wnt signaling is involved in endocrine therapy resistance in breast cancer.

Immunotherapy for breast cancer has attracted wide attention and interest, and immune checkpoint blockade is the most investigated form in more than 290 ongoing clinical trials of breast cancer immunotherapy [392]. Undoubtedly, PD-1/PD-L1 and CTLA-4 are the most attractive targets among immune checkpoint inhibitors [393]. Indeed, more than 40% of TNBCs are PD-L1 positive, and the anti-PD-L1 monoclonal antibody atezolizumab has been approved by the FDA for advanced or metastatic PD-L1-positive TNBC [394]. Nevertheless, approximately 40% of PD-L1-positive TNBCs exhibit a poor response to atezolizumab plus nab-paclitaxel treatment. Given the 10.3% complete response rate in PD-L1-positive TNBC, much more effort may be needed [394]. Wnt signaling not only controls the expression of PD-L1 [306] and CTLA-4 [307] but also blocks the tumor-immune cycle at all steps [395]. β-Catenin/STT3-dependent PD-L1 N-glycosylation stabilizes and upregulates PD-L1, which promotes breast cancer immune evasion [396]. Moreover, MMTV-Wnt1 breast tumors are classified as ‘cold tumors’, suggesting that Wnt signaling mediates immunotherapy resistance [397]. Thus, targeting Wnt signaling is a potential strategy to enhance the efficacy of cancer immunotherapy (Fig. 5 d).

Molecular agents targeting the Wnt signaling pathway in breast cancer

Hundreds of inhibitors have been developed over the past few decades. These inhibitors are generally focused on targeting Porcupine, Fzds, DVLs, TNKS 1/2, and β-Catenin/TCF or β-Catenin/coactivators.

Porcupine inhibitors have recently received great attention because of their broad-spectrum Wnt-targeted and anticancer activity. LGK974, a representative Porcupine inhibitor, is being tested in a phase I clinical trial in patients with TNBC and other Wnt-driven cancers [16, 63, 398]. Of note, GNF-6231, Porcn-IN-1, and Wnt-C59 are LGK974 analogs (Fig. 9 a and Table 4). Perturbation of Wnt–Fzd interactions is another strategy to block Wnt signaling transduction. OMP-54F28 is an Fc fusion protein that contains the extracellular N-terminal cysteine-rich domain (CRD) of Fzd8 and serves as a decoy receptor, competing with Fzd8 for all Wnts [17, 408, 409]. R-spondins are indirect activators of Wnt signaling; OMP-131R10, an anti-R-spondin-3 antibody, has entered a phase I clinical trial for solid tumor treatment (Table 5).

Fig. 9

Selected Wnt signaling inhibitors (Part 1). a Porcupine inhibitors. b Fzd inhibitors. c Wnt/Fzd/LRP inhibitor. d LGR5-specific antibody-drug conjugate. e Dvl inhibitors. f CK1α agonists. g GSK-3β agonist

Table 4 Inhibitors of Porcupine
Table 5 Inhibitors of Fzds and related factors

Targeting Fzds is also a mainstream strategy to block Wnt signaling. Niclosamide is an FDA-approved antihelminth. As an inhibitor of Fzd1, it has entered phase I/II clinical trials and could be the most promising Fzd inhibitor [411]. OMP-18R5, an antibody that targets multiple Fzds, binds to 5 of the 10 Fzds and is a potential drug for breast cancer and other solid tumors [414]. In addition, OTSA101-DTPA-111In and OTSA101-DTPA-90Y are humanized chimeric anti-Fzd10 antibodies (named OTSA-101) that are radiolabeled with Indium 111 and Yttrium 90, respectively. OTSA101-DTPA-111In is a promising Fzd10-targeted single-photon emission computed tomography (SPECT) imaging agent, while OTSA101-DTPA-90Y is a potent Fzd10-targeted agent for metastatic synovial sarcoma radiotherapy [420, 421]. Salinomycin is an FDA-approved supplement in poultry feed and kills BCSCs selectively [424]. It was subsequently proven to block Wnt-induced LRP phosphorylation [422]. LGR5 (mAb)-mc-vc-PAB-MMAE is an LGR5-specific antibody-drug conjugate (ADC). Monomethyl auristatin E (MMAE) is a tubulin-inhibiting cytotoxic drug that kills LGR5-positive cancer cells selectively [423] (Fig. 9 b-d and Table 5).

Dvls, as the main intracellular effectors of the Wnt/Fzd/LRP complex, are ideal targets. Quite a few small-molecule inhibitors have been developed for Dvl inhibition. Sulindac is the most promising Dvl inhibitor among these small-molecule inhibitors. It is an FDA-approved nonsteroidal anti-inflammatory drug that has been shown to have clinically significant anticancer effects. Sulindac is an inhibitor of not only cyclooxygenase 1/2 (COX1/2) [425] but also Dvl in the PDZ domain [426]. It is hypothesized to suppress tumor growth by blocking Dvl activity rather than prostaglandin synthesis [427, 428] (Fig. 9 e and Table 6).

Table 6 Inhibitors of Dvls

β-Catenin is the key to canonical Wnt signaling. The direct inhibition or degradation of β-Catenin is assuredly an effective strategy. Only two small molecules (MSAB [435] and NRX-252262 [436]) that directly target β-Catenin have been identified to date. Other small molecules that target β-Catenin by enhancing the formation of the destruction complex, such as activating CK1α [437,438,439], GSK-3β [440], and Axin [441], have also received full attention. Another destruction complex-independent strategy is activating Siah-1-induced β-Catenin degradation with hexachlorophene [442]. Given the critical function of Axin degradation mediated by TNKS1/2, various small-molecule inhibitors have been developed to inhibit TNKS1/2. 2X-121 (also known as E7449), the most promising TNKS1/2 inhibitor, has entered phase I/II clinical trials for breast cancer and ovarian cancer treatment [443, 444] (Fig. 9 f-g, Fig. 10 a-c and Table 7).

Fig. 10

Selected Wnt signaling inhibitors (Part 2). a Siah-1 agonist. b β-Catenin destabilizers. c TNKS1/2 inhibitors. d Axin stabilizers. e β- Catenin/TCF disruptors. f β-Catenin/CBP disruptors. g β-Catenin/TBL1 disruptor. h V-ATPase inhibitors. i Wnt signaling inhibitors with an unknown target

Table 7 Small molecules that degrade β-Catenin at the cytoplasmic level

Nuclear β-Catenin serves as a scaffold for its coactivators to bind rather than as an independent transcription factor. Thus, disrupting the interaction between β-Catenin and its coactivators is also a potent strategy to block Wnt signaling transduction. β-Catenin/TCF becomes the primary target for disruption. However, vitamin D3, as a potent β-Catenin/TCF disruptor [389, 390], has been proven to be invalid for cancer prevention and treatment [460, 461]. Disrupting the interaction between β-Catenin and BCL9 or CBP is an optional strategy to block the transcription of Wnt target genes. PRI-724, as a β-Catenin/CBP disruptor, has entered a phase I clinical trial for advanced solid tumor treatment [462]. Transducin β-like protein 1 (TBL1)–TBL1-related protein (TBLR1) and β-Catenin recruit each other, displacing the corepressors TLE and HDAC1 and resulting in the stimulation of Wnt target gene transcription [463]. BC2059 is a β-Catenin/TBL1 disruptor and has entered a phase I clinical trial for desmoid tumor treatment [464]. Intriguingly, apicularen A and bafilomycin A1, as vacuolar H+-adenosine triphosphatase (V-ATPase) inhibitors, effectively inhibit Wnt signaling [465]. In addition, although the direct targets of KY02111 [466] and SM04690 remain unknown, SM04690 has entered a phase II clinical trial for knee osteoarthritis treatment [467] (Fig. 10 d-i and Table 8).

Table 8 β-Catenin inhibitors in cancers

Challenges and opportunities

Wnt signaling activation in colorectal cancer is induced mainly by APC (73%) and CTNNB1 (5%) mutations [217], suggesting that canonical Wnt/β-Catenin signaling is the leading form of Wnt signaling in colorectal cancer. By contrast, Wnt signaling activation in breast cancer is more complicated and often involves dual effects of canonical and noncanonical Wnt signaling [22, 189, 479]. Although extensive research has been carried out, it is still unclear whether Wnt signaling can be druggable successfully for the therapeutic purposes of breast cancer.

The safety and effectiveness of Wnt signaling-targeted drugs is the most concerning issue that we have to face. Abrogation of the aberrant ‘dark side’ of Wnt signaling in breast cancer without interfering with its crucial role in tissue homeostasis and repair is undoubtedly the most desirable clinical outcome [17]. However, the majority of available Wnt inhibitors (such as LGK974) are broad spectrum, and it is challenging to achieve balance by controlling the dosage or appropriate time of drug administration. In addition, the effectiveness of Wnt signaling-targeted drugs needs to be further confirmed in clinical trials. Of note, very few inhibitors of noncanonical Wnt signaling have been identified or developed. Extensive crosstalk between noncanonical Wnt signaling and many other signaling pathways exists, making it difficult to specifically target Wnt signaling. ROCK, as a critical component of Wnt–PCP signaling (Fig. 2c), can be inhibited by the small molecule fasudil, thereby blocking Wnt–PCP signaling [480].

Furthermore, the mechanism of balance between canonical and noncanonical Wnt signaling should be addressed. For example, Wnt5a antagonizes canonical Wnt/β-Catenin signaling and exhibits tumor-suppressive activity in some circumstances [221, 481,482,483], but other studies have reported that Wnt5a controls both canonical and noncanonical Wnt signaling [15, 16, 484]. Nusse et al. explained that Wnt5a activates or inhibits β-Catenin–TCF signaling depending on the receptor context [485]. However, the switch and balance between canonical and noncanonical Wnt signaling may involve more profound mechanisms. We propose a bipolar seesaw model to illustrate this ebb and flow: various Wnt ligands and their receptors form a unique combination, and the activation of canonical or noncanonical Wnt signaling depends on this unique combination. Fzds–Dvls complex-guided downstream kinase cascades differ in canonical and noncanonical Wnt signaling. The switch mechanism may exist not only for the Wnts–Fzds complex but also for downstream kinase cascades (Fig. 11).

Fig. 11

The bipolar seesaw model between canonical and noncanonical Wnt signaling. (some compositional elements of this figure were obtained from and reference [486])

Despite the potential safety and effectiveness concerns regarding the therapeutic targeting of Wnt signaling in breast cancer, constantly emerging novel inhibitors and ongoing clinical trials may ameliorate these issues. Additionally, the application of small-molecule libraries such as Pfizer compounds and molecular docking algorithms based on structural information may accelerate this process. The decryption of underlying mechanisms, including the molecular subtype, tumor stage, and microenvironment context-dependent Wnt signaling activation, as well as the switch and balance between canonical or noncanonical Wnt signaling, is undoubtedly the rationale to ameliorate the safety and effectiveness of Wnt-targeted therapy, especially for breast cancer and other Wnt-driven cancers.


Accumulating evidence corroborates that the aberrant activation of Wnt signaling exists from breast tumor initiation to distant metastasis. An increasing number of Wnt-targeted small molecules and biologics have entered clinical trials for breast cancer treatment, suggesting that Wnt signaling is an attractive target. The identification of accurate targets and the development of safe and effective drugs are rationales for subsequent clinical trials to determine the appropriate dosage and time of drug administration. Regarding the evolution of Wnt inhibitors, monoclonal antibodies and ADCs will be the mainstream drugs in the future, which is in line with the trend of precision medicine and personalized treatment. Given the unique roles of the noncanonical Wnt pathway in breast cancer, more specific inhibitors should be developed in the future.

Although numerous studies have verified that both canonical and noncanonical Wnt signaling pathways are involved in the progression of breast cancer, there are still no available Wnt-targeted inhibitors for breast cancer treatment in a variety of clinical contexts. Efforts to seek suitable means to regulate Wnt signaling in breast cancer and other Wnt-driven cancers are still ongoing, but emerging discoveries suggest that Wnt-targeted therapy will translate soon into real therapies [90].

Availability of data and materials

Not applicable.




ABC transporters:

ATP-binding cassette transporters


Antibody-drug conjugate


Activation function 1


Aldehyde dehydrogenase 1


Activator protein 1


Adenomatous polyposis coli


Antigen-presenting cells


Activating transcription factor 2


Breast cancer-initiating cells


B cell lymphoma 9


Breast cancer resistance protein


Breast cancer stem cells


Basal-like breast cancer


Basal-like 1


Basal-like 2


Cancer-associated fibroblasts


Calcium calmodulin mediated kinase II


CapZ-interacting protein


CREB-binding protein




Cell-division cycle 42


Cadherin EGF LAG seven-pass G-type receptor 1


Cyclic guanosine monophosphate


Casein kinase 1α


Cyclooxygenase 1/2


Cysteine-rich domain


C-terminal binding protein


Cytotoxic T lymphocyte antigen 4


Cytochrome P450 2D6


Dishevelled-associated activator of morphogenesis




Ductal carcinoma in situ


Dickkopf proteins


Diaphanous 1




Extracellular matrix


Epidermal growth factor


Epithelial-mesenchymal transition


EMT transcription factors


Endoplasmic reticulum


Estrogen receptor


Fas ligand


Food and Drug Administration


Fibroblast growth factor


Forkhead box protein P3




Granulocyte colony-stimulating factor




Glycogen synthase kinase 3β


Histone deacetylases


Human epidermal growth factor receptor 2


Ligand-binding domain


Inhibitor of β-Catenin and TCF


Invasive ductal carcinoma no-special-type


Indoleamine 2,3-dioxygenase


Interferon γ


Insulin-like growth factor-binding protein 4




Invasive lobular carcinoma




Inducible nitric oxide synthase

InsP3 :

Inositol-1, 4, 5-trisphosphate


Inositol-1,4,5-trisphosphate receptors






Jun N-terminal kinase


Luminal androgen receptor


Lobular carcinoma in situ


Lymphoid Enhancer Factor 1


Leucine-rich repeat-containing G protein-coupled receptor 5


Low-density lipoprotein receptor-related proteins




Mammary stem cells


Major histocompatibility complex class I


Mitogen-activated protein kinase 3/6


Monomethyl auristatin E


Matrix metalloproteinases


Mouse mammary tumor virus


Mitogen-activated protein kinase


Multidrug resistance protein 1–5


Mesenchymal stem-like


Muscle skeletal receptor Tyr kinase


Nuclear factor of activated T cells


Nemo-like kinase


Planar cell polarity


Phosphodiesterase 6


Programmed death-ligand 1


Protein kinase G




Progesterone receptor


Protein kinase C


Phospholipase C


Protein phosphatase 2A


Protein C receptor

PtdInsP2 :



Protein Tyr kinase 7




Receptor activator of nuclear factor-κB


Receptor activator of nuclear factor-κB ligand


RAS homologue gene-family member A


RHO-associated coiled-coil-containing protein kinase


Receptor Tyr kinase-like orphan receptor 1/2


Receptor tyrosine kinases


Retinoid X receptor


Receptor-like tyrosine kinase


Skp1, Cullin1 and F-box protein β-TrCP


Sarcoplasmic/ER Ca2+ ATPases


Secreted Frizzled-related proteins


Store-operated Ca2+ entry


Single-photon emission computed tomography


Stromal interaction molecule 1/2


TGFβ-activated protein kinase 1


Tumor-associated macrophages


Transducin β-like protein 1


TBL1-related protein


T cell factor


Transducin-like enhancer


Triple-negative breast cancer


Tankyrase 1/2


Tumor necrosis factor α


TNF-related apoptosis-inducing ligand


Vacuolar H+-adenosine triphosphatase


Vang-like 2


Vitamin D receptor


Vascular endothelial growth factors


Wnt inhibitory factor 1


Wnt proteins


Wilms tumor gene on X chromosome


  1. 1.

    DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.

    PubMed  PubMed Central  Google Scholar 

  2. 2.

    Kos K, Wellenstein M, Vrijland K, Hau CS, De Visser K. PO-386 dissecting the role of regulatory T cells in metastatic breast cancer. In: Tumour Immunology. 2018:A378.373–A379.

  3. 3.

    Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, Slagter M, de Rink I, Henneman L, Kas SM, Prekovic S, Hau CS, et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572(7770):538–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4(2):68–75.

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31(1):99–109.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    van Ooyen A, Nusse R. Structure and nucleotide sequence of the putative mammary oncogene int-1; proviral insertions leave the protein-encoding domain intact. Cell. 1984;39(1):233–40.

    PubMed  Article  Google Scholar 

  7. 7.

    Cabrera CV, Alonso MC, Johnston P, Phillips RG, Lawrence PA. Phenocopies induced with antisense RNA identify the wingless gene. Cell. 1987;50(4):659–63.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Rijsewijk F, Schuermann M, Wagenaar E, Parren P, Weigel D, Nusse R. The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell. 1987;50(4):649–57.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Wend P, Runke S, Wend K, Anchondo B, Yesayan M, Jardon M, Hardie N, Loddenkemper C, Ulasov I, Lesniak MS, et al. WNT10B/beta-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med. 2013;5(2):264–79.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151(7):1542–56.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Harper KL, Sosa MS, Entenberg D, Hosseini H, Cheung JF, Nobre R, Avivar-Valderas A, Nagi C, Girnius N, Davis RJ, et al. Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature. 2016;540(7634):588–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, de Stanchina E, Massague J. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell. 2016;165(1):45–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Wang X, Jung YS, Jun S, Lee S, Wang W, Schneider A, Sun Oh Y, Lin SH, Park BJ, Chen J, et al. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nat Commun. 2016;7:10633.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Piva M, Domenici G, Iriondo O, Rabano M, Simoes BM, Comaills V, Barredo I, Lopez-Ruiz JA, Zabalza I, Kypta R, et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med. 2014;6(1):66–79.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  15. 15.

    Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, Lin Y, Li J, Kang T, Tao M, et al. Disrupting the interaction of BRD4 with diacetylated twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell. 2014;25(2):210–25.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Jiang S, Zhang M, Zhang Y, Zhou W, Zhu T, Ruan Q, Chen H, Fang J, Zhou F, Sun J, et al. WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. Cell Commun Signal. 2019;17(1):109.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  17. 17.

    Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13(7):513–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol. 2005;5(1):21–30.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Sidaway P. Prostate cancer: Wnt signalling induces resistance. Nat Rev Urol. 2015;12(11):597.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol. 2012;13(12):767–79.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259–73.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, MacBeath G. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell. 2014;159(4):844–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Prasad CP, Chaurasiya SK, Axelsson L, Andersson T. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Mol Oncol. 2013;7(5):870–83.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature. 2014;508(7494):113–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP, et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a notch-dependent mechanism. Proc Natl Acad Sci U S A. 2006;103(10):3799–804.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol. 2002;196(2):145–53.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 1994;54(10):2615–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Dale TC, Weber-Hall SJ, Smith K, Huguet EL, Jayatilake H, Gusterson BA, Shuttleworth G, O'Hare M, Harris AL. Compartment switching of WNT-2 expression in human breast tumors. Cancer Res. 1996;56(19):4320–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, Hilsenbeck SG, Rosen JM. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015;5(5):520–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Xiu DH, Liu GF, Yu SN, Li LY, Zhao GQ, Liu L, Li XF. Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/beta-catenin signaling pathway by regulating WNT2. J Exp Clin Cancer Res. 2019;38(1):94.

    PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Watanabe O, Imamura H, Shimizu T, Kinoshita J, Okabe T, Hirano A, Yoshimatsu K, Konno S, Aiba M, Ogawa K. Expression of twist and wnt in human breast cancer. Anticancer Res. 2004;24(6):3851–6.

    CAS  PubMed  Google Scholar 

  32. 32.

    Ellsworth RE, Seebach J, Field LA, Heckman C, Kane J, Hooke JA, Love B, Shriver CD. A gene expression signature that defines breast cancer metastases. Clin Exp Metastasis. 2009;26(3):205–13.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Ober EA, Verkade H, Field HA, Stainier DY. Mesodermal Wnt2b signalling positively regulates liver specification. Nature. 2006;442(7103):688–91.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Chang WL, Wu H, Chiu YK, Wang S, Jiang TX, Luo ZL, Lin YC, Li A, Hsu JT, Huang HL, et al. The making of a flight feather: bio-architectural principles and adaptation. Cell. 2019;179(6):1409–23 e1417.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Expression of Wnt3 activates Wnt/beta-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012;10(12):1597–606.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Gong C, Qu S, Lv XB, Liu B, Tan W, Nie Y, Su F, Liu Q, Yao H, Song E. BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. Nat Commun. 2014;5:5406.

    PubMed  Article  Google Scholar 

  37. 37.

    Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, Farias-Eisner R, Vadgama JV. A83-01 inhibits TGF-beta-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017;163(3):449–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465(7299):803–7.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, Alexander CM, Oesterreich S. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Res. 2016;18(1):92.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  40. 40.

    Lejeune S, Huguet EL, Hamby A, Poulsom R, Harris AL. Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res. 1995;1(2):215–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Kessenbrock K, Dijkgraaf GJ, Lawson DA, Littlepage LE, Shahi P, Pieper U, Werb Z. A role for matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling pathway. Cell Stem Cell. 2013;13(3):300–13.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Samanta S, Guru S, Elaimy AL, Amante JJ, Ou J, Yu J, Zhu LJ, Mercurio AM. IMP3 stabilization of WNT5B mRNA facilitates TAZ activation in breast Cancer. Cell Rep. 2018;23(9):2559–67.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Klemm F, Bleckmann A, Siam L, Chuang HN, Rietkotter E, Behme D, Schulz M, Schaffrinski M, Schindler S. Trumper L et al: beta-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. Carcinogenesis. 2011;32(3):434–42.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  44. 44.

    Avgustinova A, Iravani M, Robertson D, Fearns A, Gao Q, Klingbeil P, Hanby AM, Speirs V, Sahai E, Calvo F, et al. Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nat Commun. 2016;7:10305.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Sundqvist A, Morikawa M, Ren J, Vasilaki E, Kawasaki N, Kobayashi M, Koinuma D, Aburatani H, Miyazono K, Heldin CH, et al. JUNB governs a feed-forward network of TGFbeta signaling that aggravates breast cancer invasion. Nucleic Acids Res. 2018;46(3):1180–95.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Yeo EJ, Cassetta L, Qian BZ, Lewkowich I, Li JF, Stefater JA 3rd, Smith AN, Wiechmann LS, Wang Y, Pollard JW, et al. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Cancer Res. 2014;74(11):2962–73.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Mattes B, Dang Y, Greicius G, Kaufmann LT, Prunsche B, Rosenbauer J, Stegmaier J, Mikut R, Ozbek S, Nienhaus GU, et al. Wnt/PCP controls spreading of Wnt/beta-catenin signals by cytonemes in vertebrates. Elife. 2018;7.

  48. 48.

    Fang Z, Liu X, Wen J, Tang F, Zhou Y, Jing N, Jin Y. SOX21 ensures rostral forebrain identity by suppression of WNT8B during neural regionalization of human embryonic stem cells. Stem Cell Reports. 2019;13(6):1038–52.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Grainger S, Nguyen N, Richter J, Setayesh J, Lonquich B, Oon CH, Wozniak JM, Barahona R, Kamei CN, Houston J, et al. EGFR is required for Wnt9a-Fzd9b signalling specificity in haematopoietic stem cells. Nat Cell Biol. 2019;21(6):721–30.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Karner CM, Chirumamilla R, Aoki S, Igarashi P, Wallingford JB, Carroll TJ. Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis. Nat Genet. 2009;41(7):793–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Carroll TJ, Park JS, Hayashi S, Majumdar A, McMahon AP. Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. Dev Cell. 2005;9(2):283–92.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Goddard LM, Duchemin AL, Ramalingan H, Wu B, Chen M, Bamezai S, Yang J, Li L, Morley MP, Wang T, et al. Hemodynamic forces sculpt developing heart valves through a KLF2-WNT9B paracrine signaling Axis. Dev Cell. 2017;43(3):274–89 e275.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Matsunaga N, Ogino T, Hara Y, Tanaka T, Koyanagi S, Ohdo S. Optimized dosing schedule based on circadian dynamics of mouse breast Cancer stem cells improves the antitumor effects of aldehyde dehydrogenase inhibitor. Cancer Res. 2018;78(13):3698–708.

    CAS  PubMed  Google Scholar 

  54. 54.

    Chen Y, Zeng C, Zhan Y, Wang H, Jiang X, Li W. Aberrant low expression of p85alpha in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b. Oncogene. 2017;36(33):4692–705.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    El Ayachi I, Fatima I, Wend P, Alva-Ornelas JA, Runke S, Kuenzinger WL, Silva J, Silva W, Gray JK, Lehr S, et al. The WNT10B network is associated with survival and metastases in Chemoresistant triple-negative breast Cancer. Cancer Res. 2019;79(5):982–93.

    PubMed  Article  Google Scholar 

  56. 56.

    Bui TD, Rankin J, Smith K, Huguet EL, Ruben S, Strachan T, Harris AL, Lindsay S. A novel human WNT gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene. 1997;14(10):1249–53.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  57. 57.

    Dwyer MA, Joseph JD, Wade HE, Eaton ML, Kunder RS, Kazmin D, Chang CY, McDonnell DP. WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res. 2010;70(22):9298–308.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, et al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res. 2013;19(10):2723–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Clements WK, Kim AD, Ong KG, Moore JC, Lawson ND, Traver D. A somitic Wnt16/notch pathway specifies haematopoietic stem cells. Nature. 2011;474(7350):220–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  60. 60.

    Moverare-Skrtic S, Henning P, Liu X, Nagano K, Saito H, Borjesson AE, Sjogren K, Windahl SH, Farman H, Kindlund B, et al. Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat Med. 2014;20(11):1279–88.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Nalesso G, Thomas BL, Sherwood JC, Yu J, Addimanda O, Eldridge SE, Thorup AS, Dale L, Schett G, Zwerina J, et al. WNT16 antagonises excessive canonical WNT activation and protects cartilage in osteoarthritis. Ann Rheum Dis. 2017;76(1):218–26.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Tong W, Zeng Y, Chow DHK, Yeung W, Xu J, Deng Y, Chen S, Zhao H, Zhang X, Ho KK, et al. Wnt16 attenuates osteoarthritis progression through a PCP/JNK-mTORC1-PTHrP cascade. Ann Rheum Dis. 2019;78(4):551–61.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, et al. Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proc Natl Acad Sci U S A. 2013;110(50):20224–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Lin X, Liu J, Hu SF, Hu X. Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer. Cancer Manag Res. 2019;11:2203–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Lu D, Li Y, Liu QR, Wu Q, Zhang H, Xie P, Wang Q. Wls promotes the proliferation of breast cancer cells via Wnt signaling. Med Oncol. 2015;32(5):140.

    PubMed  Article  CAS  Google Scholar 

  66. 66.

    Sulli G, D’Elia E, Moroni MC. The Frizzled-ligand Norrin acts as a tumour suppressor linking oncogenic RAS signalling to p53. bioRxiv; 2019.

    Google Scholar 

  67. 67.

    Cai C, Yu QC, Jiang W, Liu W, Song W, Yu H, Zhang L, Yang Y, Zeng YA. R-spondin1 is a novel hormone mediator for mammary stem cell self-renewal. Genes Dev. 2014;28(20):2205–18.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  68. 68.

    Zhang M, Rosen JM. Developmental insights into breast Cancer Intratumoral heterogeneity. Trends Cancer. 2015;1(4):242–51.

    PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer. 2008;98(6):1147–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Durst M, Kristiansen G, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene. 2006;25(24):3479–88.

    CAS  PubMed  Article  Google Scholar 

  71. 71.

    Lo PK, Mehrotra J, D'Costa A, Fackler MJ, Garrett-Mayer E, Argani P, Sukumar S. Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol Ther. 2006;5(3):281–6.

    CAS  PubMed  Article  Google Scholar 

  72. 72.

    Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R, Dahl E. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis. 2008;29(5):991–8.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knuchel R, Dahl E. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer. 2008;7:83.

    PubMed  PubMed Central  Article  Google Scholar 

  74. 74.

    Bernemann C, Hulsewig C, Ruckert C, Schafer S, Blumel L, Hempel G, Gotte M, Greve B, Barth PJ, Kiesel L, et al. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. Mol Cancer. 2014;13:174.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  75. 75.

    Trifa F, Karray-Chouayekh S, Jmal E, Jmaa ZB, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R. Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients. Tumour Biol. 2013;34(3):1625–33.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis. 2006;27(7):1341–8.

    CAS  PubMed  Article  Google Scholar 

  77. 77.

    Mendoza-Villanueva D, Zeef L, Shore P. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res. 2011;13(5):R106.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Ryan AJ, Napoletano S, Fitzpatrick PA, Currid CA, O'Sullivan NC, Harmey JH. Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer. Br J Cancer. 2009;101(2):278–86.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  79. 79.

    Xiao Q, Chen Z, Jin X, Mao R, Chen Z. The many postures of noncanonical Wnt signaling in development and diseases. Biomed Pharmacother. 2017;93:359–69.

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR 3rd, Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003;423(6938):448–52.

    CAS  PubMed  Article  Google Scholar 

  81. 81.

    Port F, Hausmann G, Basler K. A genome-wide RNA interference screen uncovers two p24 proteins as regulators of wingless secretion. EMBO Rep. 2011;12(11):1144–52.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  82. 82.

    Buechling T, Chaudhary V, Spirohn K, Weiss M, Boutros M. p24 proteins are required for secretion of Wnt ligands. EMBO Rep. 2011;12(12):1265–72.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Aber R, Chan W, Mugisha S, Jerome-Majewska LA. Transmembrane emp24 domain proteins in development and disease. Genet Res (Camb). 2019;101:e14.

    Article  Google Scholar 

  84. 84.

    Yu J, Chia J, Canning CA, Jones CM, Bard FA, Virshup DM. WLS retrograde transport to the endoplasmic reticulum during Wnt secretion. Dev Cell. 2014;29(3):277–91.

    CAS  PubMed  Article  Google Scholar 

  85. 85.

    Banziger C, Soldini D, Schutt C, Zipperlen P, Hausmann G, Basler K. Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. Cell. 2006;125(3):509–22.

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    Fu J, Jiang M, Mirando AJ, Yu HM, Hsu W. Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for embryonic axis formation. Proc Natl Acad Sci U S A. 2009;106(44):18598–603.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  87. 87.

    Goodman RM, Thombre S, Firtina Z, Gray D, Betts D, Roebuck J, Spana EP, Selva EM. Sprinter: a novel transmembrane protein required for Wg secretion and signaling. Development. 2006;133(24):4901–11.

    CAS  PubMed  Article  Google Scholar 

  88. 88.

    Franch-Marro X, Wendler F, Guidato S, Griffith J, Baena-Lopez A, Itasaki N, Maurice MM, Vincent JP. Wingless secretion requires endosome-to-Golgi retrieval of Wntless/Evi/sprinter by the retromer complex. Nat Cell Biol. 2008;10(2):170–7.

    CAS  PubMed  Article  Google Scholar 

  89. 89.

    Port F, Kuster M, Herr P, Furger E, Banziger C, Hausmann G, Basler K. Wingless secretion promotes and requires retromer-dependent cycling of Wntless. Nat Cell Biol. 2008;10(2):178–85.

    CAS  PubMed  Article  Google Scholar 

  90. 90.

    Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–99.

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    Korkut C, Ataman B, Ramachandran P, Ashley J, Barria R, Gherbesi N, Budnik V. Trans-synaptic transmission of vesicular Wnt signals through Evi/Wntless. Cell. 2009;139(2):393–404.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  92. 92.

    Gross JC, Chaudhary V, Bartscherer K, Boutros M. Active Wnt proteins are secreted on exosomes. Nat Cell Biol. 2012;14(10):1036–45.

    CAS  PubMed  Article  Google Scholar 

  93. 93.

    Zhang L, Wrana JL. The emerging role of exosomes in Wnt secretion and transport. Curr Opin Genet Dev. 2014;27:14–9.

    PubMed  Article  CAS  Google Scholar 

  94. 94.

    Kakugawa S, Langton PF, Zebisch M, Howell S, Chang TH, Liu Y, Feizi T, Bineva G, O'Reilly N, Snijders AP, et al. Notum deacylates Wnt proteins to suppress signalling activity. Nature. 2015;519(7542):187–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Zhang X, Cheong SM, Amado NG, Reis AH, MacDonald BT, Zebisch M, Jones EY, Abreu JG, He X. Notum is required for neural and head induction via Wnt deacylation, oxidation, and inactivation. Dev Cell. 2015;32(6):719–30.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  96. 96.

    Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP, Andrew D, Nathans J, Nusse R. A new member of the frizzled family from Drosophila functions as a wingless receptor. Nature. 1996;382(6588):225–30.

    CAS  PubMed  Article  Google Scholar 

  97. 97.

    Dann CE, Hsieh JC, Rattner A, Sharma D, Nathans J, Leahy DJ. Insights into Wnt binding and signalling from the structures of two frizzled cysteine-rich domains. Nature. 2001;412(6842):86–90.

    CAS  PubMed  Article  Google Scholar 

  98. 98.

    Janda CY, Waghray D, Levin AM, Thomas C, Garcia KC. Structural basis of Wnt recognition by frizzled. Science. 2012;337(6090):59–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  99. 99.

    Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, Tomlinson A. DiNardo S: arrow encodes an LDL-receptor-related protein essential for wingless signalling. Nature. 2000;407(6803):527–30.

    CAS  PubMed  Article  Google Scholar 

  100. 100.

    Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP, He X. LDL-receptor-related proteins in Wnt signal transduction. Nature. 2000;407(6803):530–5.

    CAS  PubMed  Article  Google Scholar 

  101. 101.

    Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature. 2000;407(6803):535–8.

    CAS  PubMed  Article  Google Scholar 

  102. 102.

    Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature. 1999;398(6726):431–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  103. 103.

    Piccolo S, Agius E, Leyns L, Bhattacharyya S, Grunz H, Bouwmeester T, De Robertis EM. The head inducer Cerberus is a multifunctional antagonist of nodal. BMP and Wnt signals Nature. 1999;397(6721):707–10.

    CAS  PubMed  Google Scholar 

  104. 104.

    Rattner A, Hsieh JC, Smallwood PM, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci U S A. 1997;94(7):2859–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  105. 105.

    Itasaki N, Jones CM, Mercurio S, Rowe A, Domingos PM, Smith JC, Krumlauf R. Wise, a context-dependent activator and inhibitor of Wnt signalling. Development. 2003;130(18):4295–305.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  106. 106.

    Lintern KB, Guidato S, Rowe A, Saldanha JW, Itasaki N. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J Biol Chem. 2009;284(34):23159–68.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  107. 107.

    Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280(29):26770–5.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  108. 108.

    Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391(6665):357–62.

    CAS  PubMed  Article  Google Scholar 

  109. 109.

    Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411(6835):321–5.

    CAS  PubMed  Article  Google Scholar 

  110. 110.

    Zhu W, Shiojima I, Ito Y, Li Z, Ikeda H, Yoshida M, Naito AT, Nishi J, Ueno H, Umezawa A, et al. IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature. 2008;454(7202):345–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  111. 111.

    Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem. 1999;274(23):16180–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  112. 112.

    Rodriguez J, Esteve P, Weinl C, Ruiz JM, Fermin Y, Trousse F, Dwivedy A, Holt C, Bovolenta P. SFRP1 regulates the growth of retinal ganglion cell axons through the Fz2 receptor. Nat Neurosci. 2005;8(10):1301–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  113. 113.

    Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, Mohammed S, Heck AJ, Maurice MM, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488(7413):665–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  114. 114.

    Hao HX, Xie Y, Zhang Y, Charlat O, Oster E, Avello M, Lei H, Mickanin C, Liu D, Ruffner H, et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature. 2012;485(7397):195–200.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  115. 115.

    Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J. 1989;8(6):1711–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  116. 116.

    McCrea PD, Gumbiner BM. Purification of a 92-kDa cytoplasmic protein tightly associated with the cell-cell adhesion molecule E-cadherin (uvomorulin). Characterization and extractability of the protein complex from the cell cytostructure. J Biol Chem. 1991;266(7):4514–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  117. 117.

    McCrea PD, Turck CW, Gumbiner B. A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. Science. 1991;254(5036):1359–61.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  118. 118.

    Hulsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol. 1994;127(6 Pt 2):2061–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  119. 119.

    Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P. Association of the APC gene product with beta-catenin. Science. 1993;262(5140):1731–4.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  120. 120.

    Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A. 1995;92(7):3046–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  121. 121.

    Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL 3rd, Lee JJ, Tilghman SM, Gumbiner BM, Costantini F. The mouse fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 1997;90(1):181–92.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  122. 122.

    Hart MJ. de los Santos R, Albert IN, Rubinfeld B, Polakis P: downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol. 1998;8(10):573–81.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  123. 123.

    Mao J, Wang J, Liu B, Pan W, Farr GH 3rd, Flynn C, Yuan H, Takada S, Kimelman D, Li L, et al. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell. 2001;7(4):801–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  124. 124.

    Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 1998;17(5):1371–84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  125. 125.

    Peifer M, Pai LM, Casey M. Phosphorylation of the Drosophila adherens junction protein Armadillo: roles for wingless signal and zeste-white 3 kinase. Dev Biol. 1994;166(2):543–56.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  126. 126.

    Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 1996;10(12):1443–54.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  127. 127.

    Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108(6):837–47.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  128. 128.

    Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y, Alkalay I. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 2002;16(9):1066–76.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  129. 129.

    Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science. 1999;283(5410):2089–91.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  130. 130.

    Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science. 2007;316(5827):1043–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  131. 131.

    Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF (beta-TrCP1) ubiquitin ligase. Mol Cell. 2003;11(6):1445–56.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  132. 132.

    Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013;5(1):a007898.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  133. 133.

    Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461(7264):614–20.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  134. 134.

    Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell. 2001;7(5):927–36.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  135. 135.

    Roose J, Molenaar M, Peterson J, Hurenkamp J, Brantjes H, Moerer P, van de Wetering M, Destree O, Clevers H. The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature. 1998;395(6702):608–12.

    CAS  PubMed  Article  Google Scholar 

  136. 136.

    Cavallo RA, Cox RT, Moline MM, Roose J, Polevoy GA, Clevers H, Peifer M, Bejsovec A. Drosophila Tcf and Groucho interact to repress wingless signalling activity. Nature. 1998;395(6702):604–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  137. 137.

    Brannon M, Brown JD, Bates R, Kimelman D, Moon RT. XCtBP is a XTcf-3 co-repressor with roles throughout Xenopus development. Development. 1999;126(14):3159–70.

    CAS  PubMed  Google Scholar 

  138. 138.

    Ye F, Chen Y, Hoang T, Montgomery RL, Zhao XH, Bu H, Hu T, Taketo MM, van Es JH, Clevers H, et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat Neurosci. 2009;12(7):829–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  139. 139.

    Billin AN, Thirlwell H, Ayer DE. Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol. 2000;20(18):6882–90.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  140. 140.

    Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol. 2008;8(8):581–93.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  141. 141.

    Daniels DL, Weis WI. ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Mol Cell. 2002;10(3):573–84.

    CAS  PubMed  Article  Google Scholar 

  142. 142.

    Takemaru K, Yamaguchi S, Lee YS, Zhang Y, Carthew RW, Moon RT. Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/wingless pathway. Nature. 2003;422(6934):905–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  143. 143.

    Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C, Kelley MW, Jiang L, Tasman W, Zhang K, et al. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell. 2004;116(6):883–95.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  144. 144.

    Junge HJ, Yang S, Burton JB, Paes K, Shu X, French DM, Costa M, Rice DS, Ye W. TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling. Cell. 2009;139(2):299–311.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  145. 145.

    Ke J, Harikumar KG, Erice C, Chen C, Gu X, Wang L, Parker N, Cheng Z, Xu W, Williams BO, et al. Structure and function of Norrin in assembly and activation of a frizzled 4-Lrp5/6 complex. Genes Dev. 2013;27(21):2305–19.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  146. 146.

    Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature. 2005;438(7069):873–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  147. 147.

    Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P, Glinka A, Niehrs C. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature. 2005;438(7069):867–72.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  148. 148.

    Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z, He X. A mechanism for Wnt coreceptor activation. Mol Cell. 2004;13(1):149–56.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  149. 149.

    Wong HC, Bourdelas A, Krauss A, Lee HJ, Shao Y, Wu D, Mlodzik M, Shi DL, Zheng J. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of frizzled. Mol Cell. 2003;12(5):1251–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  150. 150.

    Murillo-Garzon V, Kypta R. WNT signalling in prostate cancer. Nat Rev Urol. 2017;14(11):683–96.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  151. 151.

    Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008;133(2):340–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  152. 152.

    Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 1997;275(5307):1790–2.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  153. 153.

    Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996;382(6592):638–42.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  154. 154.

    Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, Roose J, Destree O, Clevers H. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell. 1996;86(3):391–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  155. 155.

    Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science. 1997;275(5307):1784–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  156. 156.

    Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275(5307):1787–90.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  157. 157.

    Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J. 2000;19(8):1839–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  158. 158.

    Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, Murone M, Zullig S, Basler K. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell. 2002;109(1):47–60.

    CAS  PubMed  Article  Google Scholar 

  159. 159.

    Townsley FM, Cliffe A, Bienz M. Pygopus and legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol. 2004;6(7):626–33.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  160. 160.

    Yang Y, Mlodzik M. Wnt-frizzled/planar cell polarity signaling: cellular orientation by facing the wind (Wnt). Annu Rev Cell Dev Biol. 2015;31:623–46.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  161. 161.

    Butler MT, Wallingford JB. Planar cell polarity in development and disease. Nat Rev Mol Cell Biol. 2017;18(6):375–88.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  162. 162.

    Katoh M. WNT/PCP signaling pathway and human cancer (review). Oncol Rep. 2005;14(6):1583–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  163. 163.

    Cruciat CM, Niehrs C. Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol. 2013;5(3):a015081.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  164. 164.

    Adler PN, Zhu C, Stone D. Inturned localizes to the proximal side of wing cells under the instruction of upstream planar polarity proteins. Curr Biol. 2004;14(22):2046–51.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  165. 165.

    Jenny A, Reynolds-Kenneally J, Das G, Burnett M, Mlodzik M. Diego and Prickle regulate frizzled planar cell polarity signalling by competing for Dishevelled binding. Nat Cell Biol. 2005;7(7):691–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  166. 166.

    Narimatsu M, Bose R, Pye M, Zhang L, Miller B, Ching P, Sakuma R, Luga V, Roncari L, Attisano L, et al. Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell. 2009;137(2):295–307.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  167. 167.

    Vinson CR, Adler PN. Directional non-cell autonomy and the transmission of polarity information by the frizzled gene of Drosophila. Nature. 1987;329(6139):549–51.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  168. 168.

    Vinson CR, Conover S, Adler PN. A Drosophila tissue polarity locus encodes a protein containing seven potential transmembrane domains. Nature. 1989;338(6212):263–4.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  169. 169.

    Wang Y, Guo N, Nathans J. The role of Frizzled3 and Frizzled6 in neural tube closure and in the planar polarity of inner-ear sensory hair cells. J Neurosci. 2006;26(8):2147–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  170. 170.

    Guo N, Hawkins C, Nathans J. Frizzled6 controls hair patterning in mice. Proc Natl Acad Sci U S A. 2004;101(25):9277–81.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  171. 171.

    Usui T, Shima Y, Shimada Y, Hirano S, Burgess RW, Schwarz TL, Takeichi M, Uemura T. Flamingo, a seven-pass transmembrane cadherin, regulates planar cell polarity under the control of frizzled. Cell. 1999;98(5):585–95.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  172. 172.

    Das G, Reynolds-Kenneally J, Mlodzik M. The atypical cadherin flamingo links frizzled and notch signaling in planar polarity establishment in the Drosophila eye. Dev Cell. 2002;2(5):655–66.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  173. 173.

    Curtin JA, Quint E, Tsipouri V, Arkell RM, Cattanach B, Copp AJ, Henderson DJ, Spurr N, Stanier P, Fisher EM, et al. Mutation of Celsr1 disrupts planar polarity of inner ear hair cells and causes severe neural tube defects in the mouse. Curr Biol. 2003;13(13):1129–33.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  174. 174.

    Montcouquiol M, Rachel RA, Lanford PJ, Copeland NG, Jenkins NA, Kelley MW. Identification of Vangl2 and Scrb1 as planar polarity genes in mammals. Nature. 2003;423(6936):173–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  175. 175.

    Torban E, Kor C, Gros P. Van Gogh-like2 (strabismus) and its role in planar cell polarity and convergent extension in vertebrates. Trends Genet. 2004;20(11):570–7.

    CAS  PubMed  Article  Google Scholar 

  176. 176.

    Ciruna B, Jenny A, Lee D, Mlodzik M, Schier AF. Planar cell polarity signalling couples cell division and morphogenesis during neurulation. Nature. 2006;439(7073):220–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  177. 177.

    Nishimura T, Honda H, Takeichi M. Planar cell polarity links axes of spatial dynamics in neural-tube closure. Cell. 2012;149(5):1084–97.

    CAS  PubMed  Article  Google Scholar 

  178. 178.

    Yang W, Garrett L, Feng D, Elliott G, Liu X, Wang N, Wong YM, Choi NT, Yang Y, Gao B. Wnt-induced Vangl2 phosphorylation is dose-dependently required for planar cell polarity in mammalian development. Cell Res. 2017;27(12):1466–84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  179. 179.

    Hayes MN, McCarthy K, Jin A, Oliveira ML, Iyer S, Garcia SP, Sindiri S, Gryder B, Motala Z, Nielsen GP, et al. Vangl2/RhoA signaling pathway regulates stem cell self-renewal programs and growth in rhabdomyosarcoma. Cell Stem Cell. 2018;22(3):414–27 e416.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  180. 180.

    Fradkin LG, Dura JM, Noordermeer JN. Ryks: new partners for Wnts in the developing and regenerating nervous system. Trends Neurosci. 2010;33(2):84–92.

    CAS  PubMed  Article  Google Scholar 

  181. 181.

    Luo ZG, Wang Q, Zhou JZ, Wang J, Luo Z, Liu M, He X, Wynshaw-Boris A, Xiong WC, Lu B, et al. Regulation of AChR clustering by Dishevelled interacting with MuSK and PAK1. Neuron. 2002;35(3):489–505.

    CAS  PubMed  Article  Google Scholar 

  182. 182.

    Jing L, Lefebvre JL, Gordon LR, Granato M. Wnt signals organize synaptic prepattern and axon guidance through the zebrafish unplugged/MuSK receptor. Neuron. 2009;61(5):721–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  183. 183.

    Gordon LR, Gribble KD, Syrett CM, Granato M. Initiation of synapse formation by Wnt-induced MuSK endocytosis. Development. 2012;139(5):1023–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  184. 184.

    Lu X, Borchers AG, Jolicoeur C, Rayburn H, Baker JC, Tessier-Lavigne M. PTK7/CCK-4 is a novel regulator of planar cell polarity in vertebrates. Nature. 2004;430(6995):93–8.

    CAS  PubMed  Article  Google Scholar 

  185. 185.

    Munoz R, Moreno M, Oliva C, Orbenes C, Larrain J. Syndecan-4 regulates non-canonical Wnt signalling and is essential for convergent and extension movements in Xenopus embryos. Nat Cell Biol. 2006;8(5):492–500.

    CAS  PubMed  Article  Google Scholar 

  186. 186.

    Ohkawara B, Glinka A, Niehrs C. Rspo3 binds syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis. Dev Cell. 2011;20(3):303–14.

    CAS  PubMed  Article  Google Scholar 

  187. 187.

    Ohkawara B, Yamamoto TS, Tada M, Ueno N. Role of glypican 4 in the regulation of convergent extension movements during gastrulation in Xenopus laevis. Development. 2003;130(10):2129–38.

    CAS  PubMed  Article  Google Scholar 

  188. 188.

    Goffinet AM, Tissir F. Seven pass Cadherins CELSR1-3. Semin Cell Dev Biol. 2017;69:102–10.

    CAS  PubMed  Article  Google Scholar 

  189. 189.

    Puvirajesinghe TM, Bertucci F, Jain A, Scerbo P, Belotti E, Audebert S, Sebbagh M, Lopez M, Brech A, Finetti P, et al. Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. Nat Commun. 2016;7:10318.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  190. 190.

    Gombos R, Migh E, Antal O, Mukherjee A, Jenny A, Mihaly J. The Formin DAAM functions as molecular effector of the planar cell polarity pathway during axonal development in Drosophila. J Neurosci. 2015;35(28):10154–67.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  191. 191.

    Nakaya MA, Habas R, Biris K, Dunty WC Jr, Kato Y, He X, Yamaguchi TP. Identification and comparative expression analyses of Daam genes in mouse and Xenopus. Gene Expr Patterns. 2004;5(1):97–105.

    CAS  PubMed  Article  Google Scholar 

  192. 192.

    Aspenstrom P, Richnau N, Johansson AS. The diaphanous-related formin DAAM1 collaborates with the rho GTPases RhoA and Cdc42, CIP4 and Src in regulating cell morphogenesis and actin dynamics. Exp Cell Res. 2006;312(12):2180–94.

    PubMed  Article  CAS  Google Scholar 

  193. 193.

    Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell. 1995;81(7):1137–46.

    CAS  PubMed  Article  Google Scholar 

  194. 194.

    Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ. JNK1: a protein kinase stimulated by UV light and ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76(6):1025–37.

    CAS  PubMed  Article  Google Scholar 

  195. 195.

    Kitzing TM, Sahadevan AS, Brandt DT, Knieling H, Hannemann S, Fackler OT, Grosshans J, Grosse R. Positive feedback between Dia1, LARG, and RhoA regulates cell morphology and invasion. Genes Dev. 2007;21(12):1478–83.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  196. 196.

    Eyers CE, McNeill H, Knebel A, Morrice N, Arthur SJ, Cuenda A, Cohen P. The phosphorylation of CapZ-interacting protein (CapZIP) by stress-activated protein kinases triggers its dissociation from CapZ. Biochem J. 2005;389(Pt 1):127–35.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  197. 197.

    Peng Y, Chen Z, Chen Y, Li S, Jiang Y, Yang H, Wu C, You F, Zheng C, Zhu J, et al. ROCK isoforms differentially modulate cancer cell motility by mechanosensing the substrate stiffness. Acta Biomater. 2019;88:86–101.

    CAS  PubMed  Article  Google Scholar 

  198. 198.

    Barko S, Bugyi B, Carlier MF, Gombos R, Matusek T, Mihaly J, Nyitrai M. Characterization of the biochemical properties and biological function of the formin homology domains of Drosophila DAAM. J Biol Chem. 2010;285(17):13154–69.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  199. 199.

    Nusse R. Wnt signaling. Cold Spring Harb Perspect Biol. 2012;4:5.

    Article  CAS  Google Scholar 

  200. 200.

    Semenov MV, Habas R, Macdonald BT, He X. SnapShot: noncanonical Wnt signaling pathways. Cell. 2007;131(7):1378.